Sales Enablement
Week ending August 26, 2026
1. What’s coming up in conversations this week
- Substitution and biosimilars: People are asking, “Can the pharmacy substitute something else for Keytruda?” AI answers consistently frame substitution as possible but not automatic, depending on local rules, prescription wording, formulary, and availability. Keytruda is being described as a biologic—not a conventional generic.
- Keytruda vs. Opdivo: Prescribers or patients may ask how two PD-1 inhibitors differ in approved cancers/settings, dosing schedules, biomarkers, combinations, sequencing, and coverage.
- Keytruda vs. Tecentriq: AI is framing this as anti-PD-1 versus anti-PD-L1, with treatment choice driven by tumor type, biomarkers, line of therapy, and labeled evidence—not simply which checkpoint target is “better.”
- Label-specific administration and dosing: The resected-melanoma adjuvant regimen is repeatedly answered as 200 mg IV every 3 weeks for up to 1 year, with some answers also citing 400 mg every 6 weeks. Administration questions focus on 30-minute IV infusion, dilution, rate, premedication, and flushing.
- Safety and eligibility: Questions include AST/ALT elevations, warfarin/CYP/P-gp interactions, transplant history, autoimmune disease, pregnancy, hypersensitivity, and inflammatory bowel disease.
2. Competitive talking points
Opdivo (nivolumab) is the most prominent named competitor in the questions. AI generally says Keytruda and Opdivo are both PD-1 inhibitors but are not interchangeable in practice because indications, dosing, combinations, biomarkers, and treatment sequencing differ. AI also repeatedly circulates claims such as “more effective,” “stronger,” “best,” “superior,” and “most effective.” Treat these as AI-generated or indirect-comparison language—not verified messaging. Re-anchor the discussion to the specific cancer, stage, biomarker, line of therapy, label, evidence, and patient factors.
Tecentriq (atezolizumab) is framed as an anti-PD-L1 comparator. The practical takeaway is similarly setting-specific; avoid broad superiority claims.
3. Questions and objections to be ready for
- “Can Keytruda be substituted at the pharmacy?” High-volume theme; be ready to clarify that biologic substitution depends on jurisdiction, authorization, prescription, and formulary rules.
- “Is there a generic or biosimilar?” Seven responses raised this; distinguish generic terminology from biosimilar availability and interchangeability in the relevant market.
- “What is the labeled regimen for adjuvant resected melanoma?” All seven responses cited 200 mg IV Q3W for up to 1 year, with some also citing 400 mg Q6W; reps should use current approved labeling.
- “What are the administration instructions?” Answers disagreed on whether hypersensitivity-related guidance should be mentioned. Direct reps to the current prescribing information and site protocol rather than improvising premedication or flush advice.
4. What’s changed since last week
Volume rose from 60 to 70 responses, while the 10-question set stayed unchanged. Hedging/disclaimer language increased 50→58 and overclaim language 15→23; dosing-specific mentions rose 15→17. Inconsistency flags improved 3→2. No new question-level theme or competitor comparison can be confirmed from the trend data.
5. Recommended actions
- Add a call-prep note on Keytruda vs. Opdivo, explicitly avoiding unverified “more effective/superior” language.
- Refresh the biosimilar/substitution FAQ with market-specific escalation guidance.
- Revalidate the melanoma dosing and administration content against current labeling.
- Add a safety prompt: route AST/ALT, transplant/autoimmune, pregnancy, and hypersensitivity questions to approved medical information resources.
- No new competitor escalation is indicated; Tecentriq can remain a secondary comparison topic.